Utilization of Truenat chips in defining XDR, pre-XDR and MDR in tuberculous meningitis.
Tuberculosis (Edinb)
; 147: 102513, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38547569
ABSTRACT
SETTING AND OBJECTIVE:
To develop and evaluate newer molecular tests that identify drug resistance according to contemporary definitions in Tuberculous meningitis (TBM), the most severe form of EPTB.DESIGN:
93 cerebrospinal fluid (CSF) specimens [41 culture-positive and 52 culture-negative], were subjected to Truenat MTB Plus assay along with chips for rifampicin, isoniazid, fluoroquinolones and bedaquiline resistance. The performance was compared against phenotypic drug susceptibility testing (pDST), Line probe assay (LPA) and gene sequencing.RESULTS:
Against pDST, Truenat chips had a sensitivity and specificity of 100%; 94.47%, 100%; 94.47%, 100%; 97.14% and 100%; 100%, respectively for rifampicin, isoniazid, fluoroquinolones and bedaquiline. Against LPA, all Truenat chips detected resistant isolates with 100% sensitivity; but 2 cases each of false-rifampicin and false-isoniazid resistance and 1 case of false-fluoroquinolone resistance was reported. Truenat drug chips gave indeterminate results in â¼25% cases, which were excluded. All cases reported indeterminate were found to be susceptible by pDST/LPA.CONCLUSION:
The strategic drug resistance chips of Truenat Plus assay can contribute greatly to TB elimination by providing rapid and reliable detection of drug resistance pattern in TBM. Cases reported indeterminate require confirmation by other phenotypic and genotypic methods.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tuberculose Meníngea
/
Testes de Sensibilidade Microbiana
/
Farmacorresistência Bacteriana Múltipla
/
Tuberculose Extensivamente Resistente a Medicamentos
/
Mycobacterium tuberculosis
/
Antituberculosos
Limite:
Humans
Idioma:
En
Revista:
Tuberculosis (Edinb)
Ano de publicação:
2024
Tipo de documento:
Article